<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">ZALYTE, EGLE</style></author><author><style face="normal" font="default" size="100%">DEDONYTE, VERONIKA</style></author><author><style face="normal" font="default" size="100%">KURLINKUS, BENEDIKTAS</style></author><author><style face="normal" font="default" size="100%">SILEIKIS, AUDRIUS</style></author><author><style face="normal" font="default" size="100%">SCHEMMER, PETER</style></author><author><style face="normal" font="default" size="100%">VALIUS, MINDAUGAS</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1401-1406</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14897</style></doi><volume><style face="normal" font="default" size="100%">41</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Pancreatic ductal adenocarcinoma is one of the deadliest forms of human cancer. Since only a vast panel of cell lines can fully recapitulate disease heterogeneity, our aim was to establish a new pancreatic cancer cell line. Materials and Methods: Newly established pancreatic ductal adenocarcinoma cell line Capan-26 was characterized by assessing growth rate, tumor and stem cell marker expression, colony forming efficiency, mutations of KRAS and TP53 genes, karyotype and sensitivity to drug treatment. Results: Cell doubling time was 74 h. We detected CA19-9, CEACAM6, CD44, OCT4 and ZEB1 expression in Capan-26 cell line. Cells formed colonies in soft agar, have a deletion of KRAS exon 3 and a point mutation V172F in TP53 exon 5. They are a mixed aneuploid/polyploid population with high sensitivity to gemcitabine. Conclusion: Capan-26 is a unique cell line that may be used to study the mechanism of pancreatic cancer.</style></abstract></record></records></xml>